Our Strategy
Proven technology and a Clear Path to Market
We invest at the execution stage, not the science-experiment stage. That means venture upside with less technical risk.
Our Approach
We invest when the science is proven, and the compaany has a well vetted plan and the team to execute that plan. That means venture upside with less technical risk.
Execution-stage focus
We look for companies with demonstrated product-market fit or early sales traction, validated business models and clinical data we can have confidence in.
Pre-vetted deal flow
Our access to the very best medtech focused accelerators, angel networks and industry partners gives us a steady pipeline of companies that have already been screened by experts.
Built for the exit
Most medtech exits come through strategic acquisition. We favor companies whose products fit the portfolios of large device makers, and we work with founders to align with those buyers early.
What we look for
[Ready to Build Something Transformative?]
[If you are a founder working on a breakthrough healthcare company, we would love to hear from you.]